Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases
1
592 Route 22—Suite 1B, Pawling, NY 12564, USA
2
Northwell System, Northern Westchester Hospital, Mount Kisco, NY 10549, USA
3
Health Quest System, Sharon Hospital, Sharon, CT 06069, USA
Antibiotics 2019, 8(2), 72; https://doi.org/10.3390/antibiotics8020072
Received: 28 March 2019 / Revised: 20 April 2019 / Accepted: 25 May 2019 / Published: 30 May 2019
(This article belongs to the Special Issue Antibiotics Resistance of Borrelia)
Abstract
Three patients, each of whom had required intensive open-ended antimicrobial therapy for control of the symptoms of chronic relapsing neurological Lyme disease and relapsing babesiosis, were able to discontinue treatment and remain clinically well for periods of observation of 6–23 months following the completion of a finite course of treatment solely with disulfiram. One patient relapsed at six months and is being re-treated with disulfiram. View Full-TextKeywords:
Chronic Lyme disease; neuroborreliosis; Post-treatment Lyme disease syndrome (PTLDS); relapsing babesiosis; persistent infection; antibiotic treatment failure; disulfiram
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Liegner, K.B. Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases. Antibiotics 2019, 8, 72.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Related Articles
Article Metrics
Comments
[Return to top]
Antibiotics
EISSN 2079-6382
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert